Posted by Michael Wonder on 18 Jun 2021
European Commission approves Aubagio (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
18 June 2021 - The European Commission has approved Aubagio (teriflunomide) for the treatment of paediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis.
The approval is based on data from the Phase 3 TERIKIDS trial.
The approval confirms Aubagio as the first oral multiple sclerosis therapy for first-line treatment of children and adolescents with multiple sclerosis in the European Union.
